Guardant Health buys Israeli co MetaSight Diagnostics

Acquisition Details - US biotech company Guardant Health has acquired Israeli liquid biopsy company MetaSight Diagnostics for an immediate payment of $59 million and up to $90 million in milestone payments based on regulatory approvals and sales thresholds [1] - The acquisition was disclosed in Guardant Health's fourth quarter results, highlighting the strategic move to enhance its cancer diagnostic capabilities [1] Company Background - MetaSight was founded by Prof. Tomer Shlomi and aMoon Fund, utilizing multiomics technologies and AI to diagnose colon cancer and liver function disorders [2] - The technology is currently in the clinical trial stage and is based on a database developed in collaboration with the Maccabi Health Fund [2] Financial Insights - MetaSight has raised a total of $20 million since its founding in 2020, with notable investors including ARC and Saban Ventures [3] - The exit from MetaSight is considered modest but provides significant returns for aMoon [3] Strategic Fit - Guardant Health, valued at approximately $13.7 billion, reported revenues of about $1 billion in the current year, indicating a strong market position in cancer diagnostics [4] - The relationship between Guardant and MetaSight was fostered through presentations at conferences, where Guardant recognized the advantages of MetaSight's technology [4] Development Plans - Following the acquisition, Guardant plans to expand its operations in Israel, marking its first development center outside the US [4] - The colon cancer test developed by MetaSight is projected to be two to three years away from completing clinical trials, with additional payments contingent on successful outcomes [5]